However, only 33–44% of melanoma patients respond to monoclonal antibodies (mAb) against PD-1 [2,3,4], and 58% of melanoma patients respond to combination therapy with mAb targeting PD-1 and CTLA-4 [2]. Here, CTLA4 is linked to melanoma.